Magnesium and aspirin treatment in patients with subarachnoid haemorrhage |
| |
Authors: | W?M?van den?Bergh A?Algra G?J?E?Rinkel |
| |
Institution: | (1) Dept. of Neurology, University Medical Centre Utrecht, Utrecht, The Netherlands;(2) Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands;(3) Dept. of Intensive Care, Room Q04.460, University Medical Centre Utrecht, 85500, 3508 GA Utrecht, The Netherlands |
| |
Abstract: | Objective
Aneurysm treatment with endovascular coiling is associated with a better outcome than neurosurgical clipping in patients with
subarachnoid haemorrhage (SAH). The better outcome after coiling may decrease the risk reduction from other treatments in
these patients, and thus may increase sample sizes for current or future neuroprotective trials. The influence of the method
of aneurysm treatment was studied in our randomised MASH trial, which assessed in a factorial design the efficacy of magnesium
and aspirin in preventing delayed cerebral ischaemia (DCI) and poor outcome.
Methods
Between November 2000 and January 2004 315 patients were enrolled in the trial; 55 of them had no aneurysm treatment and were
excluded for the current analysis, 176 underwent neurosurgical and 84 endovascular treatment. The effect of treatment on the
risk of DCI was assessed by means of Cox proportional hazards modelling and that of poor outcome by means of logistic regression
analysis.
Results
The hazard ratio of DCI with aspirin was 1.4 (95 % CI 0.3 – 1.7) after coiling and 1.9 (0.8 – 4.4) after clipping, and with
magnesium 0.4 (0.1 – 1.2) after coiling and 0.8 (0.4 – 1.7) after clipping. The odds ratio of poor outcome with aspirin was
0.7 (0.2 – 2.9) after coiling and 0.8 (0.3 – 2.3) after clipping, and with magnesium 0.3 (0.1 – 1.0) after coiling and 0.8
(0.4 – 1.6) after clipping.
Conclusion
This post hoc analysis does not suggest that medical treatments are less effective after endovascular than after neurosurgical
treatment in patients with SAH, and thus do not support a need for adjusting sample size calculations in future trials.
Magnesium and Acetylsalicylic acid in Subarachnoid Haemorrhage (MASH) Study Group:
W. M. van den Bergh,A. Algra, S. M. Dorhout Mees,J. van Gijn,G. J. E. Rinkel,Dept. of Neurology,University Medical Centre
Utrecht,Utrecht, The Netherlands
Ale Algra,Julius Centre for Health Sciences and Primary Care,University Medical Centre Utrecht,Utrecht, The Netherlands
Fop van Kooten,Dept. of Neurology,Erasmus Medical Centre,Rotterdam, The Netherlands
Clemens M.F. Dirven,Dept. of Neurology,VU University Medical Centre,Amsterdam, The Netherlands
Marinus Vermeulen,Dept. of Neurology,Academic Medical CentreUniversity of Amsterdam,Amsterdam, The Netherlands
W. M. van den Bergh, MD, PhD ✉, Dept. of Intensive Care, Room Q04.460,University Medical Centre Utrecht,P.O. Box 85500,3508
GA, Utrecht, The Netherlands,Tel.: +31-30/2508350,Fax: +31-30/2522782,E-Mail: w.m.vandenbergh@umcutrecht.nl |
| |
Keywords: | controlled clinical trial subarachnoid haemorrhage aspirin magnesium |
本文献已被 SpringerLink 等数据库收录! |
|